Analysts forecast that VistaGen Therapeutics, Inc. (NASDAQ:VTGN) will announce earnings per share (EPS) of ($0.05) for the current quarter, according to Zacks. Two analysts have issued estimates for VistaGen Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.05) and the highest estimate coming in at ($0.04). VistaGen Therapeutics reported earnings of ($0.13) per share during the same quarter last year, which would indicate a positive year over year growth rate of 61.5%. The business is expected to announce its next quarterly earnings results on Monday, July 5th.
According to Zacks, analysts expect that VistaGen Therapeutics will report full year earnings of ($0.23) per share for the current financial year, with EPS estimates ranging from ($0.24) to ($0.22). For the next financial year, analysts expect that the company will report earnings of ($0.32) per share, with EPS estimates ranging from ($0.41) to ($0.22). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for VistaGen Therapeutics.
VistaGen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings results on Thursday, February 11th. The company reported ($0.07) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.02). The business had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.33 million.
Several large investors have recently added to or reduced their stakes in the company. CWM LLC bought a new stake in shares of VistaGen Therapeutics during the 1st quarter worth approximately $29,000. SG Americas Securities LLC bought a new stake in shares of VistaGen Therapeutics during the 4th quarter worth $29,000. Commonwealth Equity Services LLC bought a new position in VistaGen Therapeutics in the first quarter valued at about $38,000. GWM Advisors LLC increased its stake in shares of VistaGen Therapeutics by 60.8% in the fourth quarter. GWM Advisors LLC now owns 19,300 shares of the company’s stock valued at $37,000 after buying an additional 7,300 shares during the period. Finally, Chesley Taft & Associates LLC acquired a new stake in shares of VistaGen Therapeutics in the first quarter valued at about $46,000. Institutional investors and hedge funds own 3.13% of the company’s stock.
VTGN stock traded down $0.07 during mid-day trading on Tuesday, reaching $2.59. 2,353,512 shares of the stock traded hands, compared to its average volume of 3,166,321. The stock’s fifty day moving average is $2.19 and its 200-day moving average is $1.70. The company has a market cap of $371.25 million, a P/E ratio of -5.40 and a beta of 0.52. VistaGen Therapeutics has a 52-week low of $0.35 and a 52-week high of $3.18.
About VistaGen Therapeutics
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VistaGen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VistaGen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.